Understanding Transglutaminase 2's Role in Celiac Disease
Localizing Pathogenically Relevant Transglutaminase 2 in Celiac Disease
This work explores how a specific enzyme, Transglutaminase 2 (TG2), contributes to celiac disease in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11145816 on NIH RePORTER |
What this research studies
Celiac disease is an inflammatory condition of the small intestine caused by gluten, and currently, the only treatment is a strict gluten-free diet. This project aims to discover where TG2, an enzyme central to celiac disease, acts in the body to cause harm. We believe that TG2 found in the intestine reacts with gluten, leading to the formation of autoantibodies that are a hallmark of the disease. By understanding this process, we hope to uncover new ways to help people with celiac disease.
Who could benefit from this research
Good fit: This foundational research is for patients with celiac disease who are interested in understanding the underlying causes of their condition and future treatment possibilities.
Not a fit: Patients seeking immediate new treatments or direct clinical trial participation would not directly benefit from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this work could lead to new non-dietary treatments for celiac disease by targeting the specific actions of the TG2 enzyme.
How similar studies have performed: While the role of TG2 in celiac disease is known, this specific hypothesis about its location and mechanism of action is novel and currently untested.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Khosla, Chaitan — Stanford University
- Study coordinator: Khosla, Chaitan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.